Mallinckrodt plc and Endo Inc. have entered into a definitive agreement to combine in a stock and cash transaction to create a global, scaled, diversified pharmaceuticals company. The combination of Mallinckrodt and Endo will create a strong pharmaceutical company with a diversified portfolio, enhanced financial flexibility, and a robust footprint in the United States. The combined company will benefit from a strong balance sheet, significant synergy opportunities, and a team with specialized...